China
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs).
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase
树兰医疗递表港交所：华东最大的社会办医疗机构，另已合作14家医疗机构
“据IPO早知道消息，树兰医疗管理股份有限公司（以下简称“树兰医疗”）于2023年8月28日正式向港交所递交招股说明书，中金公司和中信证券担任联席保荐人。成立于2013年的树兰医疗作为一家集健康医疗服务、医学科研、医学教育为一体的中国科技型社会办医疗集团，截至2023年3月31日拥有并运营三家社会办综合医疗机构，并已向中国14家合作医院提供医院管理服务。同时，树兰医疗还提供数字医疗平台服务、医疗检验服务、临床试验服务、供应链服务等多项平台服务。具体来看树兰医疗的三大业务板块：其一、健康医疗服务。截至目前，树兰医疗拥有树兰(杭州)医院、树兰(安吉)医院以及树兰(衢州)医院三家社会办医综合医疗机构——其中，树兰(杭州)医院是树兰医疗于2015年12月开始运营的首家医院，其是少数获评三級甲等医院的社会办医疗机构，并于2017年成为通过JCI认证的国际医院。截至2023年3月31日，树兰(杭州)医院已开设1,000张床位，并设有46个临床专科和13个医技科室。” Continue reading at the original source, linked here.
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors.
Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities
Innovac Therapeutics, an mRNA therapeutics company, today announced the completion of an $18 million Series Pre-A financing
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.
A China fund from Fidelity is beating the crowd. How it plans to keep doing it
Fidelity’s China Focus Fund is setting up for another year of outperformance, after ranking first last year among China equity funds tracked by Morningstar.
SoftBank-backed Neumora Therapeutics files for U.S. IPO
Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japan's SoftBank, on Friday filed for an initial public offering of its shares in New York.
Gina Raimondo hails ‘important beginning’ for US-China ties, wraps up trip at Boeing, Disneyland in Shanghai
US Commerce Secretary Gina Raimondo hailed 'an important beginning' for Beijing and Washington to manage tensions on Wednesday, while also calling on China to address market concerns for American firms.
China says the best way to ‘de-risk’ is to restore stability with the U.S.
China’s Ministry of Commerce said Thursday that restoring stability in U.S.-China trade relations is the best way to 'de-risk' — a twist to a term that’s become popular in international politics.
